Cabozantinib
EGFR Inhibitor
DB08875
Approved Indication
For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
3
Targets
0
Resistance Mutations
4
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.
Details
DrugBank ID
DB08875 ↗
Approval Date
2012-11-29
Molecular Weight
501.514 g/mol
Drug Class
EGFR Inhibitor
ATC Codes
L01XE26
Synonyms
—
PubChem
CID: 25102847 ↗
ChEMBL
CHEMBL2105717 ↗
SMILES
COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
ADMET Profile
Computing properties…
Drug References (DrugBank)